According to the latest report published by Credence Research, Inc. “Impetigo Treatment Market – Growth, Future Prospects and Competitive Analysis, 2018-2026,” the global Impetigo treatment market was valued at US$ 448.6 Mn in 2017 and expected to reach US$ 856.2 Mn by 2026, expanding at a CAGR of 7.3% from 2018 to 2026.
[Note: Our Free Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology are also Included]
The global market for impetigo treatment has been shown to be worth US$ 856.2 million by 2026 from US$ 448.6 million in 2017, growing at CAGR by 7.3 per cent between 2018 and 2026 during the forecast period. Impetigo is a superficial infection of the skin caused by gram-positive bacteria, Staphylococcus aureus or Streptococcus pyogenes. Infection is reported to be highly prevalent in children under 14 years of age. According to Asha C. Bowen, et al. “The Global Epidemiology of Impetigo: a Systematic Review of the Prevalence of Impetigo and Pyoderma in the Population.” PLoS One 2015; 10(8), the global impetigo prevalence has increased from 111 million in 2000 to 162 million in 2015, with the majority of cases occurring in the region of Oceania, especially in low and middle-income countries. High impetigo prevalence is the primary factor that accounts for the surge in the impetigo treatment market. In addition, awareness of pediatric skin diseases and growing healthcare infrastructure are fuelling market growth. However, the increasing resistance of microbes due to frequent use is a major concern and burdens manufacturers to produce effective antibiotics, thus contributing to market growth.
Based on the drug class, the global market for impetigo therapy is divided into cephalosporins, fusidane, lincosamide, penicillin, penicillin-like antibiotics, pleuromutilin, pseudomonic acid A, quinolone, sulfonamides and folic acid inhibitors, and tetracyclines. In 2017, the penicillin segment dominated the global market for impetigo treatment due to the high preference of physicians. The penicillin-like antibiotic segment was similar to the penicillin market and accounted for more than 15 per cent of the global share in terms of value.
Based on the geographical demarcation, North America led the global market in 2017, with more than 34% of its market share, in terms of value, and expected to retain its lead over the forecast period. Well-established healthcare infrastructure and a growing awareness of skin diseases are key factors in North America’s supremacy. In terms of value, Europe tailed North America, followed by the Asia-Pacific region. As fusidane / fusidic acid is not available in the United States, the treatment method varies from the European region.
The global impetigo treatment market witness the presence of numerous players as the treatment includes antibiotics only. Several global and local manufacturers compete in the market and form a fragmented market.
Some of the key players in the market include GlaxoSmithKline plc, Karalex Pharma, LLC, Leo Pharma A/S, Lupin Limited, NovaBay Pharmaceuticals, Inc., Pfizer, Inc., Ranbaxy Laboratories Limited, Roche Holding AG, SANDOZ GmbH, Taro Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.